Form 4 Roivant Sciences Ltd. For: Sep 24 Filed by: Gold Daniel Allen
Roivant Sciences Ltd. (ROIV)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Roivant Sciences Ltd. (NASDAQ: ROIV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Roivant Sciences Ltd. (NASDAQ: ROIV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.MarketBeat
- Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%GlobeNewswire
- FOX Nation Taps Vivek Ramaswamy to Host New Series "Truths with Vivek Ramaswamy" Premiering September 22 [Yahoo! Finance]Yahoo! Finance
- Roivant Sciences Ltd. (NASDAQ: ROIV) had its price target raised by analysts at Bank of America Co. from $12.00 to $12.50. They now have a "neutral" rating on the stock.MarketBeat
ROIV
Earnings
- 8/8/24 - Beat
ROIV
Sec Filings
- 9/26/24 - Form 4
- 9/26/24 - Form 4
- 9/25/24 - Form 144
- ROIV's page on the SEC website